IN2015DN00820A - - Google Patents
Info
- Publication number
- IN2015DN00820A IN2015DN00820A IN820DEN2015A IN2015DN00820A IN 2015DN00820 A IN2015DN00820 A IN 2015DN00820A IN 820DEN2015 A IN820DEN2015 A IN 820DEN2015A IN 2015DN00820 A IN2015DN00820 A IN 2015DN00820A
- Authority
- IN
- India
- Prior art keywords
- relates
- present
- macular degeneration
- baclofen
- combinations
- Prior art date
Links
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 abstract 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960004047 acamprosate Drugs 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 229960000794 baclofen Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672893P | 2012-07-18 | 2012-07-18 | |
| PCT/EP2013/065209 WO2014013025A1 (en) | 2012-07-18 | 2013-07-18 | Baclofen and acamprosate based therapy of macular degeneration disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00820A true IN2015DN00820A (en:Method) | 2015-06-12 |
Family
ID=48794112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN820DEN2015 IN2015DN00820A (en:Method) | 2012-07-18 | 2013-07-18 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9545389B2 (en:Method) |
| EP (1) | EP2874617B1 (en:Method) |
| JP (1) | JP6271539B2 (en:Method) |
| KR (1) | KR20150058159A (en:Method) |
| CN (1) | CN104780917B (en:Method) |
| AU (1) | AU2013291970B2 (en:Method) |
| BR (1) | BR112015001090A2 (en:Method) |
| CA (1) | CA2879114A1 (en:Method) |
| EA (1) | EA029157B1 (en:Method) |
| ES (1) | ES2729208T3 (en:Method) |
| IL (1) | IL236737B (en:Method) |
| IN (1) | IN2015DN00820A (en:Method) |
| MX (1) | MX364232B (en:Method) |
| NZ (1) | NZ704280A (en:Method) |
| SG (1) | SG11201500309VA (en:Method) |
| WO (1) | WO2014013025A1 (en:Method) |
| ZA (1) | ZA201500663B (en:Method) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| EP3062782A1 (en) | 2013-10-30 | 2016-09-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| WO2015121218A1 (en) | 2014-02-11 | 2015-08-20 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| KR20110097942A (ko) | 2003-08-20 | 2011-08-31 | 제노포트 인코포레이티드 | 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법 |
| WO2005027950A1 (en) * | 2003-09-12 | 2005-03-31 | Ray And Terry's Health Products, Inc. | Eye nutritional supplement |
| ES2405329T3 (es) | 2003-12-30 | 2013-05-30 | Xenoport, Inc. | Síntesis de profármacos de carbarnato de aciloxialquilo y productos intermedios de los mismos |
| ATE511392T1 (de) | 2007-01-11 | 2011-06-15 | Xenoport Inc | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit |
| WO2009004082A2 (en) * | 2007-07-05 | 2009-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticonvulsive pharmaceutical compositions |
| US20090082464A1 (en) | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| WO2009033069A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090099253A1 (en) | 2007-10-15 | 2009-04-16 | Xenoport, Inc. | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
| WO2009061934A1 (en) | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
| US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
| WO2009096985A1 (en) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
| WO2010089355A1 (en) | 2009-02-04 | 2010-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| CA2753057C (en) * | 2009-03-03 | 2018-09-11 | Xenoport, Inc. | Sustained release oral dosage forms of an r-baclofen prodrug |
| JP2012524065A (ja) | 2009-04-17 | 2012-10-11 | ゼノポート，インコーポレーテッド | ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体 |
| SI2560631T1 (sl) * | 2011-03-01 | 2014-06-30 | Pharnext | Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti |
-
2013
- 2013-07-18 EP EP13737622.4A patent/EP2874617B1/en not_active Not-in-force
- 2013-07-18 WO PCT/EP2013/065209 patent/WO2014013025A1/en not_active Ceased
- 2013-07-18 IN IN820DEN2015 patent/IN2015DN00820A/en unknown
- 2013-07-18 MX MX2015000777A patent/MX364232B/es active IP Right Grant
- 2013-07-18 JP JP2015522100A patent/JP6271539B2/ja not_active Expired - Fee Related
- 2013-07-18 KR KR1020157004145A patent/KR20150058159A/ko not_active Ceased
- 2013-07-18 ES ES13737622T patent/ES2729208T3/es active Active
- 2013-07-18 BR BR112015001090A patent/BR112015001090A2/pt not_active IP Right Cessation
- 2013-07-18 NZ NZ704280A patent/NZ704280A/en not_active IP Right Cessation
- 2013-07-18 CN CN201380048663.4A patent/CN104780917B/zh not_active Expired - Fee Related
- 2013-07-18 SG SG11201500309VA patent/SG11201500309VA/en unknown
- 2013-07-18 AU AU2013291970A patent/AU2013291970B2/en not_active Ceased
- 2013-07-18 US US14/415,994 patent/US9545389B2/en not_active Expired - Fee Related
- 2013-07-18 CA CA2879114A patent/CA2879114A1/en not_active Abandoned
- 2013-07-18 EA EA201500143A patent/EA029157B1/ru not_active IP Right Cessation
-
2015
- 2015-01-15 IL IL236737A patent/IL236737B/en active IP Right Grant
- 2015-01-29 ZA ZA2015/00663A patent/ZA201500663B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX364232B (es) | 2019-04-16 |
| JP6271539B2 (ja) | 2018-01-31 |
| US9545389B2 (en) | 2017-01-17 |
| US20150238452A1 (en) | 2015-08-27 |
| CA2879114A1 (en) | 2014-01-23 |
| EP2874617A1 (en) | 2015-05-27 |
| CN104780917B (zh) | 2017-09-08 |
| ES2729208T3 (es) | 2019-10-30 |
| EA029157B1 (ru) | 2018-02-28 |
| HK1209335A1 (en) | 2016-04-01 |
| IL236737A0 (en) | 2015-02-26 |
| KR20150058159A (ko) | 2015-05-28 |
| IL236737B (en) | 2018-12-31 |
| MX2015000777A (es) | 2015-10-14 |
| BR112015001090A2 (pt) | 2017-06-27 |
| SG11201500309VA (en) | 2015-02-27 |
| AU2013291970A1 (en) | 2015-02-19 |
| EA201500143A1 (ru) | 2015-05-29 |
| NZ704280A (en) | 2017-06-30 |
| EP2874617B1 (en) | 2019-02-27 |
| CN104780917A (zh) | 2015-07-15 |
| ZA201500663B (en) | 2016-10-26 |
| JP2015522601A (ja) | 2015-08-06 |
| AU2013291970B2 (en) | 2017-09-28 |
| WO2014013025A1 (en) | 2014-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN00288A (en:Method) | ||
| IN2014DN00286A (en:Method) | ||
| IN2014MN00093A (en:Method) | ||
| IN2014MN01378A (en:Method) | ||
| IN2014DN06792A (en:Method) | ||
| MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
| MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
| PH12013502240B1 (en) | Novel compounds as modulators of protein kinase | |
| NZ720949A (en) | Methods and compositions for treating aging-associated conditions | |
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| MX348495B (es) | Metodos y composiciones para el control de malezas. | |
| IN2014DN05885A (en:Method) | ||
| GB201210699D0 (en) | Nutritional food | |
| HK1206393A1 (en) | Compositions and methods for diagnosis and treatment of pervasive developmental disorder | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| MX357656B (es) | Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias. | |
| MX361773B (es) | Agentes de ligación a tlr3. | |
| MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. | |
| NZ704280A (en) | Baclofen and acamprosate based therapy of macular degeneration disorders | |
| WO2013163562A3 (en) | Compositions and methods for treating ptsd and related diseases | |
| MX369774B (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| MX2017004986A (es) | Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2 para terapias oculares. | |
| WO2012166659A3 (en) | Anti-emr1 antibodies | |
| WO2013101509A3 (en) | Hsp70 fusion protein conjugates and uses thereof |